NEW YORK (TheStreet) -- Mylan (MYL) - Get Report is not the bad guy for raising EpiPen prices, it's just the poster child for all of the pharmaceutical bad guys that are dramatically raising drug prices, Citron Research founder Andrew Left said on CNBC's "Halftime Report" on Friday afternoon. 

For that reason, Left has a long position on Mylan, although he is known for his successful shorts. 

"For the Senate to bring in Mylan and that to become the next victim of public outcry over pharmaceutical pricing is completely outrageous," he claimed. 

Mylan has become the "whipping boy" because it's a well-known brand, Left claimed. The Senate is using it as an example to show people that it's doing something about the drug pricing war, but it "picked on the wrong company with Mylan."

The real culprit is Mallinckrodt (MNK), which Left is short on. 

Sen. Claire McCaskill (D-MO) should "go two miles from her office and go look at Mallinckrodt and they'll see a true abuser of the system." 

TheStreet Recommends

Separately, TheStreet Ratings objectively rated this stock according to its "risk-adjusted" total return prospect over a 12-month investment horizon. Not based on the news in any given day, the rating may differ from Jim Cramer's view or that of this articles's author.

TheStreet Ratings team rates Mylan as a Hold with a ratings score of C. The primary factors that have impacted the team's rating are mixed - some indicating strength, some showing weaknesses, with little evidence to justify the expectation of either a positive or negative performance for this stock relative to most other stocks.

You can view the full analysis from the report here: MYL

Image placeholder title

MYL

data by

YCharts